Huan J. Zhu

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.

Srđan Verstovšek, Olatoyosi Odenike, Bart L. Scott et al. · Blood · 2009 · 77 citations

Medicine, Hematology, Pharmacology +13

Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis

Rami S. Komrokji, Martha Wadleigh, John F. Seymour et al. · Blood · 2011 · 66 citations

Medicine, Hematology, Pharmacology +8

MicroRNA expression profile in Treg cells in the course of primary immune thrombocytopenia

Yuandong Zhu, Huan J. Zhu, Xiaobao Xie et al. · Journal of Investigative Medicine · 2019 · 18 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity.

Anas Younes, Michelle A. Fanale, Peter McLaughlin et al. · Blood · 2009 · 11 citations

Medicine, Oncology, Pharmacology +14